Enzymatica AB Expands Distribution Into Iraq and Jordan
The Swedish biotech firm will launch its ColdZyme mouth spray in Middle Eastern markets through a new local partnership.
Updated on Oct. 26, 2026 in Healthcare
Live Poll
Do you trust that new international health products entering your local market benefit your community?
Swedish biotech firm Enzymatica AB has signed an exclusive distribution agreement with MedonyX to bring its ColdZyme mouth spray to markets in Iraq and Jordan. The product, which treats common cold and flu symptoms, is slated for a regional launch pending necessary regulatory approvals.
Why it matters
This partnership leverages local expertise to navigate regulatory frameworks in Iraq and Jordan, marking a strategic expansion for the developer of the enzyme-based barrier spray. Expanding into new international markets allows the manufacturer to increase reach for its consumer healthcare product.
The agreement includes the rights to market and sell the mouth spray in Iraq and Jordan, with the distributor backed by MMDS, which has operated since 2012. Market entry remains subject to local regulatory approval in both countries.
The players
Enzymatica AB
A Swedish biotech company that develops enzyme-based healthcare products including the ColdZyme mouth spray.
MedonyX
A distributor backed by MMDS that specializes in pharmacist-led regulatory, marketing, and sales operations.
MMDS
An Amman-based firm founded in 2012 that provides the regulatory and distribution infrastructure for the partnership.
The details
The partnership mandates that MedonyX utilize its pharmacist-led teams to handle the registration, marketing, and distribution processes in the target regions. ColdZyme functions as an enzyme-based barrier in the mouth and throat to address cold and flu symptoms. By integrating the product into established local distribution channels, the firms intend to manage the compliance steps required for market entry.
Timeline
2012: The year MMDS was founded.
Q1 2027: Expected product launch in Iraq and Jordan.
Market Landscape
This move follows a trend of European healthcare firms seeking growth in Middle Eastern markets by partnering with established local operators. The deal highlights the strategy of navigating regional regulatory nuances through local third-party firms rather than direct international investment.
Operators in the consumer health space should note that regional expansion into Iraq and Jordan often hinges on establishing local pharmacist-led partnerships to handle complex registrations. Tracking the first-quarter 2027 launch date will provide a benchmark for how effectively these regulatory pathways can be cleared.
The takeaway
Expanding into emerging pharmaceutical markets requires deep, localized knowledge of regulatory filing processes. Monitor the performance of the Q1 2027 launch to gauge the effectiveness of partnering with locally established firms for brand entry.
Further reading
Learn more about the latest developments in Healthcare.
Source note: This article includes information reported by Iraq Business News | All the latest business news from Iraq.
Live Poll
Do you trust that new international health products entering your local market benefit your community?
